➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Boehringer Ingelheim
Harvard Business School
McKesson
Mallinckrodt

Last Updated: June 2, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Prexasertib


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Prexasertib?

Prexasertib is an investigational drug.

There have been 14 clinical trials for Prexasertib. The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2016.

The most common disease conditions in clinical trials are Neoplasms, Carcinoma, Non-Small-Cell Lung, and Neoplasm Metastasis. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and Khanh Do.

There are three US patents protecting this investigational drug and sixty-four international patents.

Recent Clinical Trials for Prexasertib
TitleSponsorPhase
A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and RhabdomyosarcomaMemorial Sloan Kettering Cancer CenterPhase 1/Phase 2
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain TumorsEli Lilly and CompanyPhase 1
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain TumorsSt. Jude Children's Research HospitalPhase 1

See all Prexasertib clinical trials

Clinical Trial Summary for Prexasertib

Top disease conditions for Prexasertib
Top clinical trial sponsors for Prexasertib

See all Prexasertib clinical trials

US Patents for Prexasertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Prexasertib   Start Trial 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitfile (S)-lactate monohydrate Eli Lilly and Company (Indianapolis, IN)   Start Trial
Prexasertib   Start Trial Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA)   Start Trial
Prexasertib   Start Trial 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-- carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts Eli Lilly and Company (Indianapolis, IN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Medtronic
Boehringer Ingelheim
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.